1
项与 Anti-CD123 CAR T-cell therapy(Nanjing Legend Biotechnology Co., Ltd.) 相关的临床试验Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of anti-CD123 CAR-T cells in treating patients diagnosed with refractory/relapsed acute leukemia in a dose-escalation way.
100 项与 Anti-CD123 CAR T-cell therapy(Nanjing Legend Biotechnology Co., Ltd.) 相关的临床结果
100 项与 Anti-CD123 CAR T-cell therapy(Nanjing Legend Biotechnology Co., Ltd.) 相关的转化医学
100 项与 Anti-CD123 CAR T-cell therapy(Nanjing Legend Biotechnology Co., Ltd.) 相关的专利(医药)
100 项与 Anti-CD123 CAR T-cell therapy(Nanjing Legend Biotechnology Co., Ltd.) 相关的药物交易